Canadian General Investments: Investment Update - Unaudited

TORONTO, Canada, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (CGI) (TSX: CGI) (LSE: CGI) reports on an unaudited basis that its net asset value per share (NAV) at September 30, 2024 was $65.37 resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 18.9% and 22.4%, respectively. These compare with the 17.2% and 26.7% returns of the benchmark S&P/TSX Composite Index on a total return basis for the same periods.

The Company employs a leveraging strategy, by way of bank borrowing, with the intent to enhance returns to common shareholders. As at September 30, 2024, the leverage represented 12.8% of CGI’s net assets, down from 15.1% at the end of 2023 and 15.4% at September 30, 2023.

The closing price for CGI’s common shares at September 30, 2024 was $39.95, resulting in year-to-date and 12-month share price returns, with dividends reinvested, of 17.4% and 15.2%, respectively.

The sector weightings of CGI’s investment portfolio at market as of September 30, 2024 were as follows:

Information Technology	23.0%
Industrials	22.2%
Financials	13.6%
Materials	13.1%
Energy	11.9%
Consumer Discretionary	10.0%
Real Estate	4.4%
Communication Services	1.5%
Cash & Cash Equivalents	0.3%

The top ten investments which comprised 39.4% of the investment portfolio at market as of September 30, 2024 were as follows:

NVIDIA Corporation	7.0%
Canadian Pacific Kansas City Limited	4.3%
TFI International Inc.	4.2%
Apple Inc.	3.9%
WSP Global Inc.	3.7%
The Descartes Systems Group Inc.	3.6%
West Fraser Timber Co. Ltd.	3.6%
Franco-Nevada Corporation	3.2%
Mastercard Incorporated	3.1%
Dollarama Inc.	2.8%

FOR FURTHER INFORMATION PLEASE CONTACT:
Jonathan A. Morgan
President & CEO
Phone: (416) 366-2931
Fax: (416) 366-2729
e-mail: [email protected]
website: www.canadiangeneralinvestments.ca       

Source: Canadian General Investments, Limited

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy
• BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthc
• American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus Nephritis